Gene Amplification and Deletion in Pancreatic Cancer

胰腺癌中的基因扩增和缺失

• 批准号: 7099096
• 负责人: JONATHAN R POLLACK
• 金额: $ 29.37万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-19 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7099096
• 关键词: DNA methylation; RNA interference; athymic mouse; biological signal transduction; cell morphology; cell motility; clinical research; comparative genomic hybridization; fluorescent in situ hybridization; gene deletion mutation; gene expression profiling; human subject; immunocytochemistry; microarray technology; molecular oncology; natural gene amplification; neoplasm /cancer genetics; neoplasm /cancer invasiveness; neoplastic growth; pancreas neoplasms; tissue /cell culture; ubiquitin protein ligase; xenotransplantation

DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth-most common cause of cancer-related death in the United States. Understanding the genetic abnormalities underlying pancreatic cancer pathogenesis is critical for developing robust clinical assays for early detection, as well as for mechanistic therapeutic strategies. The long term objectives of this study are to identify pathogenetic gene amplifications and deletions in pancreatic cancer, and to functionally characterize the underlying oncogenes and tumor suppressor genes. Array-based comparative genomic hybridization (array CGH) on pancreatic cancer cell lines defined previously unrecognized DNA amplifications and deletions, harboring novel candidate oncogenes and tumor suppressor genes. These studies identified two candidate cancer genes in particular whose altered copy number and expression may contribute to pancreatic cancer: SMURF1, which modulates TGFp signaling, and DKK3, likely involved in WNT signaling. A major goal of this proposal is to characterize the function of SMURF1 and DKK3 in pancreatic cancer development and progression through studying tumor growth in cell culture and in mice. A second major goal is to extend array CGH studies to primary pancreatic tumors, thereby discovering additional candidate pancreatic cancer genes. These studies will further knowledge of the role of gene amplification and deletion in pancreatic cancer, in particular in regards to the TGFp and WNT pathways, and may provide new strategies for therapeutic intervention. The specific scientific aims of this proposal are: (1) to characterize the role of gene amplification in the pathogenesis of pancreatic cancer, focusing on SMURF1, a modulator of TGFp signaling; (2) to characterize the role of gene deletion in the development of pancreatic cancer, focusing on DKK3, a potential modulator of WNT signaling; and (3) to identify additional novel DNA amplifications and deletions in pancreatic cancer, by array CGH analysis of primary pancreatic tumors.

描述（由申请人提供）：胰腺癌是美国与癌症相关死亡的第四大原因。了解胰腺癌发病机理的遗传异常对于开发鲁棒的临床检测至关重要，以供早期检测以及机械治疗策略。这项研究的长期目标是确定胰腺癌的致病基因扩增和缺失，并在功能上表征基础的癌基因和肿瘤抑制基因。基于阵列的比较基因组杂交（阵列CGH）在胰腺癌细胞系上定义了先前未识别的DNA扩增和缺失，具有新颖的候选癌基因和肿瘤抑制基因。这些研究发现了两个候选癌症基因，它们的拷贝数和表达可能改变可能导致胰腺癌：Smurf1调节TGFP信号传导和DKK3，可能涉及WNT信号传导。该提案的主要目的是表征SMURF1和DKK3在胰腺癌发育和进展中通过研究细胞培养和小鼠的肿瘤生长的功能。第二个主要目标是将阵列CGH研究扩展到原发性胰腺肿瘤，从而发现其他候选胰腺癌基因。这些研究将进一步了解基因扩增和缺失在胰腺癌中的作用，尤其是在TGFP和WNT途径方面，并且可能为治疗干预提供新的策略。该提案的具体科学目的是：（1）表征基因扩增在胰腺癌发病机理中的作用，重点是Smurf1，这是TGFP信号传导的调节剂； （2）表征基因缺失在胰腺癌发展中的作用，重点是DKK3，DKK3是Wnt信号的潜在调节剂； （3）通过对原发性胰腺肿瘤的阵列CGH分析来鉴定胰腺癌中其他新型的DNA扩增和缺失。